Wedmont Private Capital Acquires 2,779 Shares of Eli Lilly and Company $LLY

Wedmont Private Capital grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 17.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 18,843 shares of the company’s stock after buying an additional 2,779 shares during the quarter. Wedmont Private Capital’s holdings in Eli Lilly and Company were worth $22,039,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Intelligence Driven Advisers LLC boosted its stake in shares of Eli Lilly and Company by 9.7% during the third quarter. Intelligence Driven Advisers LLC now owns 725 shares of the company’s stock valued at $839,000 after purchasing an additional 64 shares during the period. Journey Retirement Planning & Investment Management LLC lifted its holdings in Eli Lilly and Company by 13.9% during the 3rd quarter. Journey Retirement Planning & Investment Management LLC now owns 797 shares of the company’s stock valued at $923,000 after buying an additional 97 shares in the last quarter. Central Bank & Trust Co. lifted its holdings in Eli Lilly and Company by 1.0% during the 3rd quarter. Central Bank & Trust Co. now owns 2,219 shares of the company’s stock valued at $2,568,000 after buying an additional 21 shares in the last quarter. WoodTrust Financial Corp boosted its position in Eli Lilly and Company by 1.5% in the 3rd quarter. WoodTrust Financial Corp now owns 3,371 shares of the company’s stock valued at $3,901,000 after buying an additional 50 shares during the period. Finally, Brown Shipley& Co Ltd boosted its position in Eli Lilly and Company by 0.7% in the 3rd quarter. Brown Shipley& Co Ltd now owns 4,750 shares of the company’s stock valued at $5,496,000 after buying an additional 33 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by insiders.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: New Phase 3b TOGETHER-PsO data showed that combining Taltz with Zepbound produced broader biological effects than Taltz alone in adults with psoriasis and obesity. By Week 36, the combination changed 482 proteins versus 140 with Taltz alone and affected 467 genes versus 16, alongside improved skin clearance and weight loss. The findings could strengthen Lilly’s case for treating interconnected metabolic and inflammatory conditions. New Phase 3b data on Lilly’s Taltz and Zepbound
• Positive Sentiment: Analyst Cantor Fitzgerald raised its Eli Lilly price target to $1,440 from $1,410 and maintained an Overweight rating, implying meaningful upside based on continued obesity-drug demand and pipeline execution. Cantor Fitzgerald raises pharma price targets
• Positive Sentiment: Recent coverage continues to highlight strong Zepbound demand, potential retatrutide and Foundayo catalysts, and expansion in oncology and Alzheimer’s research. Lilly’s second-quarter revenue growth of roughly 48% and raised outlook provide fundamental support for the long-term growth narrative.
• Neutral Sentiment: Despite its growth profile, Lilly trades below its historical average forward earnings multiple. That may indicate a valuation opportunity, but it also reflects investor concerns about competition, pricing pressure and whether the company’s exceptional growth can continue.
• Neutral Sentiment: Lilly and Nvidia reportedly plan to commit up to $1 billion to an artificial-intelligence drug-discovery laboratory. The initiative may improve future research productivity, although it is unlikely to materially affect near-term earnings. Nvidia and Eli Lilly AI drug-discovery lab
• Negative Sentiment: Lilly’s largest shareholder filed to sell approximately $347 million of stock. The transaction may be routine portfolio management, but its size can raise concerns about insider or major-holder confidence and create additional supply.
• Negative Sentiment: The company is facing a lawsuit from a patient alleging stomach problems linked to Mounjaro and Trulicity. Litigation creates regulatory, legal and reputational risk, although the financial impact remains uncertain.

Eli Lilly and Company Stock Up 0.7%

Shares of NYSE LLY opened at $1,177.57 on Friday. Eli Lilly and Company has a 12-month low of $783.85 and a 12-month high of $1,292.65. The stock’s fifty day simple moving average is $1,174.35 and its two-hundred day simple moving average is $1,097.02. The stock has a market capitalization of $1.11 trillion, a PE ratio of 39.52, a price-to-earnings-growth ratio of 1.44 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the previous year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts expect that Eli Lilly and Company will post 36.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LLY. Guggenheim raised their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research report on Friday, September 18th. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a research note on Thursday, September 17th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Berenberg Bank set a $1,400.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, September 15th. Finally, Leerink Partners upped their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.